Skip to main content

Advertisement

SpringerLink
Log in

Gemcitabine and Other New Cytotoxic Drugs: Will Any Find Their Way Into Primary Therapy?

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Primary treatment for classic Hodgkin lymphoma (HL) remains highly effective with chemotherapy alone or combined-modality therapy. The limitations of therapy have been related to toxicity and efficacy in subsets of patients. The introduction of a number of new and novel cytotoxic agents has provided opportunities for investigating their use in the treatment of HL. This article briefly reviews current primary treatment strategies for HL and examines the existing data for both new cytotoxic agents and other selected novel agents in the treatment of HL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •Of importance ••Of major importance

  1. American Cancer Society: Cancer Facts & Figures 2009. Atlanta: American Cancer Society; 2009. Available at http://www.cancer.org/downloads/STT/500809web.pdf. Accessed April 5, 2010.

  2. Ferme C, Eghbali H, Meerwaldt J, et al.: Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 2007, 357:1916–1927.

    Article  CAS  PubMed  Google Scholar 

  3. Canellos GP, Anderson JR, Propert KJ, et al.: Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992, 327(21):1478–1984.

    Article  CAS  PubMed  Google Scholar 

  4. Canellos GP, Niedzwiecki D: Long-term follow-up of Hodgkin’s disease trial. N Engl J Med 2002, 346(18):1417–1418.

    Article  PubMed  Google Scholar 

  5. Duggan DB, Petroni GR, Johnson JL, et al.: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 2003, 21:607–614.

    Article  CAS  PubMed  Google Scholar 

  6. Noordijk EM, Carde P, Dupouy N, et al.: Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006, 24:3128–3135.

    Article  PubMed  Google Scholar 

  7. Engert A, Franklin J, Eich HT, et al.: Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: Final results of the GHSG HD7 trial. J Clin Oncol 2007, 25:3495–3502.

    Article  CAS  PubMed  Google Scholar 

  8. •• Engert A, Diehl V, Pluetschow A, et al.: Two cycles of ABVD followed by involved field radiotherapy with 20 gray is the new standard of care in the treatment of patients with early-stage Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group HD10 [abstract]. Blood (ASH Annual Meeting Abstracts) 2009, 114:716a. The mature results of this study establish a new standard of care for the GHSG in the treatment of patients with early-stage HL, which reduces both the number of cycles of chemotherapy and the radiation dose without sacrificing efficacy.

    Google Scholar 

  9. Straus DJ: The case for chemotherapy only for localized Hodgkin lymphoma. Oncologist 2009, 14:1225–1231.

    Article  CAS  PubMed  Google Scholar 

  10. Canellos GP: Is chemotherapy alone for early Hodgkin lymphoma an emerging therapeutic option? Oncologist 2009, 14:1167–1168.

    Article  PubMed  Google Scholar 

  11. DeVita V, Simon R, Hubbard S, et al.: Curability of advanced Hodgkin’s disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980, 92:587–595.

    Google Scholar 

  12. Bonadonna G, Zucali R, Monfardini S, et al.: Combination chemotherapy of Hodgkin’s disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975, 36:252–259.

    Article  CAS  PubMed  Google Scholar 

  13. Johnson P, Radford J, Cullen M, et al.: Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin’s lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 2005, 23:9208–9218.

    Article  CAS  PubMed  Google Scholar 

  14. Bartlett N, Rosenberg S, Hoppe R, et al.: Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin’s disease: a preliminary report. J Clin Oncol 1995, 13:1080–1088.

    CAS  PubMed  Google Scholar 

  15. Diehl V, Franklin J, Hasenclever D, et al.: BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin’s lymphoma: interim report from a trial of the German Hodgkin’s Study Group. J Clin Oncol 1998, 16:3810–3821.

    CAS  PubMed  Google Scholar 

  16. •• Engert A, Diehl V, Franklin J, et al.: Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GSHG HD9 study. J Clin Oncol 2009, 27:4548–4554. The mature results from this study suggest excellent efficacy of the escalated BEACOPP regimen. This serves as the foundation for an ongoing international trial examining ABVD versus escalated BEACOPP to more clearly establish the standard of care for patients with advanced-stage HL.

    Article  PubMed  Google Scholar 

  17. Ballova V, Ruffer JU, Haverkamp H, et al.: A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (study HD9 elderly). Ann Oncol 2005, 16:124–131.

    Article  CAS  PubMed  Google Scholar 

  18. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin’s disease. N Engl J Med 1998, 339:1506–1514.

    Article  CAS  PubMed  Google Scholar 

  19. Hutchings M, Loft A, Hansen M, et al.: FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006, 107:52–59.

    Article  CAS  PubMed  Google Scholar 

  20. Gallamini A, Rigacci L, Merli F, et al.: The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica 2006, 91:475–481.

    PubMed  Google Scholar 

  21. Noble S, Goa KL: Gemcitabine: a review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 1997, 54:447–472.

    Article  CAS  PubMed  Google Scholar 

  22. Santoro A, Bredenfeld H, Devizzi L, et al.: Gemcitabine in the treatment of refractory Hodgkin’s disease: results of a multicenter phase II study. J Clin Oncol 2000, 18:2615–2619.

    CAS  PubMed  Google Scholar 

  23. Venkatesh H, DiBella N, Flynn TP, et al.: Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin’s lymphoma. Clin Lymphoma 2004, 5:110–115.

    Article  CAS  PubMed  Google Scholar 

  24. Zinzani PL, Bendandi M, Stefoni V, et al.: Value of gemcitabine treatment in heavily pretreated Hodgkin’s disease patients. Haematologica 2000, 85:926–929.

    CAS  PubMed  Google Scholar 

  25. Baetz T, Belch A, Couban S, et al.: Gemcitabine, dexamethasone, and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003, 14:1762–1767

    Article  CAS  PubMed  Google Scholar 

  26. Kuruvilla J, Nagy T, Pintile M, et al.: Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 2006, 106:353–360.

    Article  CAS  PubMed  Google Scholar 

  27. • Barlett N, Niedzwiecki D, Johnson J, et al.: Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol 2007, 18:1071–1079. This study established GVD as a well-tolerated, effective salvage regimen for patients with relapsed HL.

    Article  Google Scholar 

  28. Santoro A, Magagnoli M, Spina M, et al.: Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haemotologica 2007, 92:35–41.

    Article  CAS  Google Scholar 

  29. • Cole P, Schwartz C, Drachtman R, et al.: Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a Children's Oncology Group Report. J Clin Oncol 2009, 27:1456–1461. The results of this small phase 2 study show an ORR with the GV combination similar to that seen in other gemcitabine-containing salvage regimens with three or more agents. Based upon this result, further study of the GV combination may be warranted.

    Article  CAS  PubMed  Google Scholar 

  30. Younes A, Romaguera J, Hagemeister F, et al.: A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003, 98:310–314.

    Article  CAS  PubMed  Google Scholar 

  31. Oki Y, Pro B, Fayad LE, et al.: Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 2008, 112:831–836.

    Article  CAS  PubMed  Google Scholar 

  32. Mendler J, Kelly J, Voci S, et al.: Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 2008, 19:1759–1764.

    Article  CAS  PubMed  Google Scholar 

  33. Friedberg JW, Neuberg D, Kim H, et al.: Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity. Cancer 2003, 98:978–982.

    Article  CAS  PubMed  Google Scholar 

  34. Bredenfeld H, Franklin J, Nogova L, et al.: Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2004, 22:2424–2429.

    Article  CAS  PubMed  Google Scholar 

  35. • Straus D, LaCase A, Juweid M, et al.: Doxorubicin, vinblastine, and gemcitabine (AVG), a novel regimen excluding bleomycin for the treatment of early stage Hodgkin lymphoma (HL): results of CALGB 50203 [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:214a. Results with this regimen for primary treatment that omits bleomycin (in an effort to mitigate pulmonary toxicity) were inferior to what would be expected with standard ABVD.

    Google Scholar 

  36. Toh HC, Sun L, Koh CH, et al.: Vinorelbine induces apoptosis and caspase-3 (CPP32) expression in leukemia and lymphoma cells: a comparison with vincristine. Leuk Lymphoma 1998, 31:195–208.

    CAS  PubMed  Google Scholar 

  37. Devizzi L, Santoro A, Bonfante V, et al.: Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin’s disease. Ann Oncol 1994, 5:817–820.

    CAS  PubMed  Google Scholar 

  38. Ferme C, Bastion Y, Lepage E, et al.: The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin’s disease. Ann Oncol 1995, 6:517–518.

    Google Scholar 

  39. Bonfante V, Viviani S, Devizzi L, et al.: High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin’s disease. Eur J Haematol Supp 2001, 64:51–55.

    CAS  Google Scholar 

  40. Benchekroun S, Chouffai Z, Harif M, et al.: Clinical study of navelbine activity in Hodgkin’s disease. Phase II study. In Navelbine (Vinorelbine): Update and New Trends. Montrouge: Pierre Fabre Oncologie; Libbey Eurotext 1991, 261–264.

  41. Jones RJ, Lin L, Gocke C, et al.: Clonotypic B cells circulate in Hodgkin's lymphoma (HL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:230a.

  42. • Copeland A, Yumei C, Fanale M, et al.: Final report of a phase II study of rituximab plus ABVD for patients with newly diagnosed advanced stage classical Hodgkin lymphoma: results of long follow-up and comparison to institutional historical data [abstract]. Blood (ASH Annual Meeting Abstracts) 2009, 114:1680a. These data serve as the basis for an ongoing multicenter randomized trial comparing ABVD with RABVD in newly diagnosed patients with advanced-stage classic HL. The long-term results of this trial may help to further clarify the role of rituximab in the initial treatment of HL

    Google Scholar 

  43. Herold M, Anger G, Höche D, Kastner R: [Preliminary results of cyclically alternating chemotherapy (CVPP/DBVCy) in advanced Hodgkin's disease.] [Article in German.] Med Klin (Munich) 1987, 82:345–349.

    CAS  Google Scholar 

  44. Moskowitz A, Hamlin P, Gerecitano J, et al.: Bendamustine is highly active in heavily pre-treated relapsed and refractory Hodgkin lymphoma and serves as a bridge to allogeneic stem cell transplant [abstract]. Blood (ASH Annual Meeting Abstract) 2009, 114:720a.

    Google Scholar 

  45. Kuruvilla J, Taylor D, Wang L, et al.: Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:3052a.

    Google Scholar 

  46. Fehniger T, Larson S, Trinkaus K, et al.: A phase II multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts) 2009, 114:3693a.

    Google Scholar 

  47. Corazzelli G, De Filippi R, Capobianco G, et al.: Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma. Am J Hematol 2010, 85:87–90.

    PubMed  Google Scholar 

  48. Lane A, Chabner B: Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 27:5459–5468.

    Article  CAS  PubMed  Google Scholar 

  49. Shabason J, Tofilon P, Camphausen K: HDAC inhibitors in cancer care. Oncology 2010, 24:180–185.

    Google Scholar 

  50. Kirschbaum MK, Goldman BH, Zain JM, et al.: Vorinostat (suberoylanilide hydroxamic acid) in relapsed or refractory Hodgkin lymphoma: SWOG 0517 [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:2574a.

    Google Scholar 

  51. Bociek RG, Kuruvilla J, Pro B, et al.: Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin lymphoma (HL) [abstract]. J Clin Oncol (ASCO Annual Meeting Proceedings) 2008, 26:8507a.

    Google Scholar 

  52. DeAngelo D, Spencer A, Ottman O, et al.: Panobinostat has activity in treatment refractory Hodgkin lymphoma [abstract]. European Hematology Association, 14th Congress Abstracts 2009:abstract 1064.

  53. Younes A, Tee-Chuan O, Ribrag V, et al.: Efficacy of panobinostat in phase II study in patients with relapsed/refractory Hodgkin lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant [abstract]. Blood (ASH Annual Meeting Abstracts) 2009, 114:923a.

    Google Scholar 

  54. • Younes A, Forero-Torres A, Barlett NL, et al.: Multiple complete responses in a phase I dose-escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:1006a. These results formed the basis of a recently completed pivotal study of SGN-35 in patients with relapsed HL after ASCT. Given these promising results, studies of SGN-35 as part of primary therapy or following primary therapy for HL are warranted.

    Google Scholar 

Download references

Acknowledgments and Disclosure

Dr. Friedberg is a Scholar in Clinical Research of the Leukemia and Lymphoma Society and is supported, in part, by the University of Rochester SPORE in Lymphoma (CA-130805). He is a member of a Data and Safety Monitoring Board sponsored by Eli Lilly, and previously served on an advisory board for Seattle Genetics. No other potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. James P. Wilmot Cancer Center, Division of Hematology/Oncology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 704, Rochester, NY, 14642, USA

    David W. Dougherty & Jonathan W. Friedberg

Authors
  1. David W. Dougherty
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan W. Friedberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan W. Friedberg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dougherty, D.W., Friedberg, J.W. Gemcitabine and Other New Cytotoxic Drugs: Will Any Find Their Way Into Primary Therapy?. Curr Hematol Malig Rep 5, 148–156 (2010). https://doi.org/10.1007/s11899-010-0054-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-010-0054-x

Keywords

Search

Navigation